Subscribe to Newsletter

Subspecialties

Subspecialties Professional Development

First Lady of the Gonin Medal

Sitting Down With Alice McPherson,founder of the Retina Research Foundation

Subspecialties Professional Development

Serving Patients who have Learning Disabilities

| Rachel Pilling

People with learning disabilities are ten times more likely to have serious sight problems than the general population and often fail to receive the same standard of care. Here’s how to avoid some of the pitfalls and some tips for a successful doctor-patient relationship.

Subspecialties Cornea / Ocular Surface

Combatting Corneal Steepening

| Mark Hillen

A three-year study of progressive keratoconus has shown that corneal cross-linking is associated with sustained delay in disease progression.

Subspecialties Glaucoma

Glaucoma’s Fifty Shades of Grey

| Mark Hillen

Actually, it's 1,000 shades – that’s what the human eye can discriminate in adapting to bright and dark condition. How does glaucoma affect this ability?

Subspecialties Retina

Benchmarking DME

| Mark Hillen

What does analysis of the last five years of literature on diabetic macular edema tell us about the priorities of the field and the major contributors to it?

Subspecialties Glaucoma

Glaucoma Management Strategies

| Mark Hillen

In many patients, glaucoma cannot be controlled with eyedrops, but a range of surgical techniques and drainage devices can help.

Subspecialties Glaucoma

POAG predisposition

| Mark Hillen

Predictors for primary open-angle glaucoma in a South Indian population.

Subspecialties Retina

Interleukin for a better wet AMD therapy

| Mark Hillen

Subcutaneously-administrated IL-18 works well to reverse choroidal neovascularization (in mice).

Subspecialties Retina

The Vitreomacular Interface Influences AMD Outcomes

| Isabelle Leach

Evidence is stacking up that the configuration of the VMI alters the functional and anatomic efficacy of anti-VEGF drugs.

Subspecialties Cornea / Ocular Surface

Reinventing the Eyedrop: the story of Cationorm

| Mark Hillen

Making an optimal eyedrop formulation has always been a major challenge; compromises had to be made. Nanodroplet emulsion technology has changed that. Here’s how.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: